Figure 3. Individual profiles of total Unified Parkinson’s Disease Rating Scale (UPDRS) (parts I–III) scores.

Individual profiles of total UPDRS (parts I–III) scores over months to years, and before (filled symbols) and after (unfilled symbols) need for dopaminergic therapy was determined for each participant randomized to (A) placebo, or to Inosine titrated to a (B) mildly (mild) or (C) moderately (mod) elevated serum urate range, and stratified by sex. Estimated rate (indicated by a dashed line in each profile) of UPDRS total score change prior to initiation of dopaminergic treatment were based on the shared-baseline, random-slopes mixed model. Total UPDRS scores following determination of need for levodopa or other antiparkinsonian medication (indicated by unfilled Post-Rx symbols) often were lower (better) than what was projected (dashed line) rate of change based on total UPDRS scores prior to the determination, consistent with symptomatic benefit in some patients.